sixsense strategy group’s Post

#Phispers Week 17 - Weekly Pharma News Recap Sponsored by EUROAPI Bonjour, - ImmunityBio, Inc. bags maiden FDA nod for bladder cancer med Anktiva. - Ipsen, Skyhawk Therapeutics ink potential US$ 1.8 bn deal for rare neurological diseases. - Boehringer Ingelheim, Ochre Bio sign potential US$ 1 bn deal to develop liver therapies. - Sanofi’s rilzabrutinib triumphs in late-stage trial for blood disorder. #Phispers in a minute - PharmaCompass.com's Weekly News Recap #healthcare #pharmaceuticals #pharmanews #pharmaceuticalindustry #innovation #management #digitalmarketing #technology #startups #marketing #sales #strategy #networking #pharma #biotechnology #pharmacompass

Previous post edits with the correct YouTube video: The Early Development Estimand Nexus (EDEN) from the Estimands in Oncology WG shares in this fourth short video of the series how to implement the ICH-E9 addendum and which opportunities it presents in early clinical development studies (see the first comment if you missed the previous videos).   Francois Mercier and Stefan Englert explain in this video why it’s beneficial to embrace the estimand thinking in early clinical development and how to define estimands and associated estimators in this setting of Phase 1a (dose-escalation) and Phase 1b (expansion cohorts) studies.   Keep an eye on EFSPI (European Federation of Statisticians in the Pharmaceutical Industry), PSI: Statisticians in the Pharmaceutical Industry and ASA Biopharmaceutical Section as they will be posting the next videos soon!    #collaboration #oncoestimand   https://lnkd.in/g6bSJAvq

💡 Unveiling Insights into the "Platin-Based Chemotherapies and Nephrotoxicity Market" 💡 Platin-based chemotherapies, widely used in cancer treatment, come with a critical challenge: nephrotoxicity. DelveInsight Business Research LLP's latest report dives deep into the market landscape, highlighting unmet needs, emerging therapies, and innovations aimed at mitigating kidney-related side effects. The leading Platin based chemotherapies and nephrotoxicity Companies such as Matrix Biomed, Renibus Therapeutics Inc, SBI Pharmaceuticals, and others. 📊 Explore the evolving trends, market dynamics, and promising advancements shaping this crucial domain @ https://lnkd.in/eTNMh7HK #DelveInsight #PlatinBasedChemotherapies #Nephrotoxicity #PharmaceuticalResearch #OncologyTherapies #MarketAnalysis #HealthcareInnovation

👋 As we continue our Meet the Team series, we’re delighted to introduce Oliver Day, Behavioural Scientist, who is also a key part of our Oncology team, HRW ORBIT. 🧠 Ollie shared with us how his background in Behavioural science interplays with his role in HRW’s oncology research, including the psychological and behavioural factors that are seen throughout oncology. 👉 Scroll through to read Ollie’s full interview 🖇️ To find out more about the key factors to consider when testing oncology concepts, like loss aversion, which can help marketing teams understand how to be conscious of these concepts in order to facilitate attention, communication and persuasion, click the link below: https://lnkd.in/ezTKTf4y ✍ Let us know in the comments who you’d love to hear from next! #meettheteam #meettheteamseries #carousel #oncology #oncologycare #behaviouralscience #behavioralscience #Bsci #behaviouralscientist #patientinfluencers #behaviouralbias #behavioralbias #healthcare #healthcaremarketresearch #marketresearch #research #pharma #pharmaceutical #pharmaresearch

TLDR Biotech for June 20 - 23 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 & 𝐋𝐚𝐛𝐞𝐥𝐬: Bristol Myers Squibb lands FDA ok for colorectal cancer treatment 🎉 + 7 more stories 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Melodia Therapeutics acquires pre-clinical cathepsin C inhibitor from Alivexis 💼 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Eli Lilly presents positive Ph3 data for GIP/GLP-1 in sleep apnea 💤 + 1 more story 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Rapafusyn Pharmaceuticals raises $28M Series A 💰 + 1 more story 𝐈𝐏𝐎𝐬: Tectonic Therapeutics debuts on NASDAQ via reverse merger with AVROBIO 📈 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Biocon seeks partner for testing Ozempic generics in China 🤝 + 1 more story 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐀𝐜𝐜𝐞𝐬𝐬: Vertex and NHS reach reimbursement deal for cystic fibrosis treatments 🏥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: Study shows AI can accelerate clinical trial enrolments 🤖 𝐋𝐚𝐲𝐨𝐟𝐟𝐬: Ginkgo Bioworks cuts 158 staff, with more expected 😟 + 1 more story All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gxxHMN5q Or subscribe to get it straight to your inbox: https://lnkd.in/gh68uhTQ #tldrbiotech #biotechnews #pharmanews

"Breaking News! Our latest research paper reveals alarming findings on the adverse effects of dopamine category drugs, linking them to an increased risk of cancer. This cohort retrospective study shelds light on the critical need for healthcare professionals to weigh the benefits and risks of these medications. Read our paper to learn more about this crucial discovery! (www.ajprr.com) #DopamineCategoryDrugs #CancerRisk #Healthcare #Research #Pharmacology"

TLDR Biotech for June 20 - 23 𝐀𝐩𝐩𝐫𝐨𝐯𝐚𝐥𝐬 & 𝐋𝐚𝐛𝐞𝐥𝐬: Bristol Myers Squibb lands FDA ok for colorectal cancer treatment 🎉 + 7 more stories 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭: Melodia Therapeutics acquires pre-clinical cathepsin C inhibitor from Alivexis 💼 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬: Eli Lilly presents positive Ph3 data for GIP/GLP-1 in sleep apnea 💤 + 1 more story 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐞𝐬: Rapafusyn Pharmaceuticals raises $28M Series A 💰 + 1 more story 𝐈𝐏𝐎𝐬: Tectonic Therapeutics debuts on NASDAQ via reverse merger with AVROBIO 📈 𝐏𝐚𝐫𝐭𝐧𝐞𝐫𝐬𝐡𝐢𝐩𝐬: Biocon seeks partner for testing Ozempic generics in China 🤝 + 1 more story 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐀𝐜𝐜𝐞𝐬𝐬: Vertex and NHS reach reimbursement deal for cystic fibrosis treatments 🏥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡: Study shows AI can accelerate clinical trial enrolments 🤖 𝐋𝐚𝐲𝐨𝐟𝐟𝐬: Ginkgo Bioworks cuts 158 staff, with more expected 😟 + 1 more story All this and more in today's TLDR Biotech newsletter - link to the latest issue: https://lnkd.in/gKDcuBXa Or subscribe to get it straight to your inbox: https://lnkd.in/gecXctqM #tldrbiotech #biotechnews #pharmanews

💊 Which Pharma M&A Deal in 2024 Will Transform Healthcare the Most? 💊 Vertex, AstraZeneca, Roche, J&J, and Biogen are making bold moves in autoimmune, oncology, metabolic, and immune-mediated diseases. These strategic deals are set to redefine the future of patient care and innovation. These moves underscore how major players are innovating and adapting to tackle complex diseases. As we move forward, it’s clear that the M&A landscape will continue to evolve, driving scientific breakthroughs and expanding treatment options for patients worldwide. What are your thoughts on these deals? Which one do you think will have the biggest impact? #Pharma #HealthcareInnovation #MergersAndAcquisitions #FutureOfHealthcare

After inking an up to $6 billion partnership with Poseida Therapeutics in 2022, Roche is now paying $1 billion upfront to acquire all of its off-the-shelf cell therapy and genomic medicines partner. The Swiss pharma giant is gaining a pipeline of oncology, autoimmune and neurology treatment candidates. “We do really think this is only the beginning. And when you think about it this way, then the answer becomes almost a foregone conclusion that there is so much complementarity, there is so much potential, we should become one,” Aviv Regev, head of research and early development at Genentech, said in an interview with Endpoints News. #roche #poseida #sandiegobiotech #biotech #pharma #biotechacquisition #allogeneic #offtheshelf #celltherapy #genomicmedicines #multiplemyeloma #hemophiliaa #hereditaryangioedema

Thoughts on this? >> IGM scraps oncology work to focus on autoimmune, loses three executives >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #productmarketing #pharma #pharmaceutical